clinical trial · NCT07318324
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
M.D. Anderson Cancer Center·phase1·not yet recruiting·n = 31
Phase IBAvutometinibRAS PathwayEndometrialAvutometinibdefactinibEverolimus
brief summary
To find the recommended dose of the combination of avutometinib, defactinib, and everolimus in patients with endometrial cancer that is recurrent and has abnormal RAS activity. The safety and effects of this combination will also be studied.
started
Jun 3, 2026
primary completion
Aug 1, 2028
completion
Aug 1, 2030
last updated
Jan 6, 2026
detailed description
Primary Objectives To identify the recommended phase 2 dosing (RP2D) of the combination of avutometinib, defactinib and everolimus in participants with recurrent, RAS pathway mutant endometrial cancer.
Secondary Objectives To evaluate the tolerability of the RP2D of avutometinib, defactinib and everolimus including dose limiting toxicities that occur during cycle 1.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol